Scancell Share Discussion Threads

[888icb] 02/7/2024 10:32

This is very positive news which has clearly not been properly understood by the selling that has taken this down 5% this morning. Today’s news makes a good deal happening sooner more likely. I think this is capture well in a post on lse:
“ This RNS is absolutely positive.

It takes the CLN’s out of the picture if and when Scancell begin discussing a sale or partnership of the Immunobody Platform.

It takes pressure off having to do a deal or seek finance in the next 12 months.

It sets up the Registration Trial as a ‘go it alone’ prospect. If a buyer steps forward the price will now be a multiple of what it could have been if Redmile want their money back in November 2025.

It also tells me that what they have seen so far in the iSCIB+ cohort is the same or better that SCIB1.

‘Another Additional Brick in the Wall’ …..

[marcusl2] 02/7/2024 09:14

Positive news.

[sci102] 02/7/2024 08:23

Assuming they are honest, they don't want "their money back" you buffoons, they want the pps to rise as much as possible, convert at 13p and maximise profit. You can't even ramp properly ffs 🤣🤣🤣

[sci102] 02/7/2024 07:25

Seems like a vote of confidence from Redmile, then again I'm not a finance person. Will be interesting to see if there are any operational changes in the next period.

[sci102] 01/7/2024 12:11

Scancell said by email they use the checkmate [melanoma] trials as a benchmark.

They evaluated ORR at week 25, so ORR in this case requires 2 verifications minimum after the first response at 13 weeks, in line with recist 1.1 guidelines for multiple verifications in phase 2 trials.

In a subsequent checkmate trial, they evaluated ORR until progression, change of treatment or death (standard r 1.1). If none of the above, they report the best response. If PR but then more than 50% growth from nadir, then PD. Up to 20 months.

So, whichever the case, we do need to know how (at least) some of the patients they have already reported on are doing + early PFS data + the results from the patients they have recruited since Sept 2023.

PS: they did not know how to properly report this on the clinical trial register lmao

[marcusl2] 01/7/2024 09:34

Well that is the start of H2, the business end of the year. Hopefully excellent data from the trials within the next few months.

[ivyspivey] 30/6/2024 10:54

Morning have to agree with Nana on picking out the most salient point of the paper

[inanaco] 30/6/2024 10:35

TF ref LSE its not about Covidity its about a new construct using our targets but if you actually read it, it does NOT generate covid antibodies as such its not really of interest to us at all


"""" Further in vivo studies with a bivalent SARS-CoV-2 pDNA vaccine revealed that only the mixed formulation led to strong antigen specific T-cell responses, however this did not translate into the presence of serum antibodies """"

[ivyspivey] 29/6/2024 18:29

I base most o my decisions on probability but there are a lot of shares out there and there are extra influences on probability than news

[inanaco] 29/6/2024 18:08

so you don't trust Probabilities ... not even Rucks Effort ?

[ivyspivey] 29/6/2024 17:20

Am happy with my current holding in both.
I actually think that the share price here has a very real chance of being higher than HVO in 12 months time hence do not want to bet.
Will buy here more on next news

[inanaco] 29/6/2024 14:50

New bet Ivy ? or you sold HVO bought SCLP ?

[marcusl2] 29/6/2024 13:44

I`ll bet anyone £100 that we are higher than 11p by Xmas ;-)

[ivyspivey] 29/6/2024 11:17

Checked and thanks.
In a years time I think you will be well rewarded

[inanaco] 29/6/2024 10:45

Ivy i paid yesterday afternoon check your bank

[ivyspivey] 29/6/2024 09:18

Hi Moljen,
Only up for family wedding so only one spare nigh.
Got an ex mail this morning so will look at presentation later and see if it is one tgat was done earlier in month

focusIR Features with: SEEEN, GreenRoc Resources, Scancell, Firering Strategic Minerals, Rainbow Rare Earths, Andrada Mining, Tribe Technology

[moljen] 28/6/2024 23:31

Hi Ivy, hope enjoying Northumberland …. go a few miles up the A1 and try The Cook and Barker at Newton on The Moor

Appears continued good news here but wtf is it going to turn into £'s?

Million dollar or £8 question???

If does what it says on tin that's possibly too cheap … we've been waiting a long time to find out, what's another year or so

[ivyspivey] 28/6/2024 19:18

Hi Nana,
Our bet is now over so if you want to send the £100 like last year that will be great.
Have a nice w/ end

[marcusl2] 27/6/2024 14:30

Immune cell killing a cancer cell

[marcusl2] 27/6/2024 12:39

Oct 16 17:30 Basel

Clinical update on the DC targeting melanoma vaccine, SCIB1 and the Modi-1 vaccine targeting citrullination
Therapeutic Vaccine Development immunotherapy
Lindy Durrant

[marcusl2] 27/6/2024 12:35

We should have plenty of data by 15th October.



Festival of BiologicsFestival of Biologics
2,956 followers2,956 followers
3h • 3 hours ago
Follow

Learn more about the DC targeting melanoma vaccine!

Lindy Durrant, Joint CEO and CSO of Scancell Ltd, will discuss the latest clinical updates on the DC targeting melanoma vaccine, SCIB1, and the Modi-1 vaccine targeting citrullination during her upcoming session at the Festival of Biologics Basel!

Her session promises to provide valuable insights into the vaccine's new updates and trial results. It's an opportunity not to be missed.

Book now to participate in her session and receive the latest updates 👉